Audit: QRS - Betaine for Health & Longevity

Audit conducted on 23/07/2026 00:52 using AI4L / Grok 4

Summary

Items	Count
Total	91
Passed	81
Failed	0
N/A	10
Pass Rate	100.00%

Total = Passed + Failed + N/A
Pass Rate = Passed / (Passed + Failed) × 100
N/A items are excluded from the pass rate calculation

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All QRS claims (at-a-glance, protocol, benefits, risks, gates, monitoring, qualitative) trace to ER passages.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Cautious phrasing preserved (e.g., “theoretical interaction”, “speculative”, “weak or conflicted”).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications and benefit/risk tiers match ER strength; no strengthening or softening.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Benefits, risks, contraindications, and interactions kept in their ER categories.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, expert names, or brand names introduced.
1.6	The QRS does not introduce new attributions.	🟢	No new attributions added.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Objective, cautious framing matches ER conclusion and section tone.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Expert, accessible, data-driven tone throughout.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Presents evidence as a guide, not prescriptive orders.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No medical-advice framing in QRS variables; footer disclaimer present.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Content is descriptive/presentational rather than recommendatory.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person address to the reader.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Plain language in at-a-glance and gates; technical terms limited to ER-derived labels.
2.8	Information is presented in a concise and very compact manner	🟢	Compact bullets, cells, and tier lines.
2.9	It DOES NOT address the reader directly	🟢	No “you”/reader address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Framing suits proactive longevity-oriented adults (labs, training, modest doses).
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Protocol/monitoring detail assumes willingness to dose, train, and recheck labs.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Not general-population framed.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Risk/benefit weighting matches ER (homocysteine/strength vs weak fat-loss/liver signals).
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	Uses “longevity”; no “anti-aging” voice.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Clinical/scientific register; “labs”/”gut” echo ER conclusion wording.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	Fixed headings, gate titles, tier labels, and table headers unchanged.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Full set of template data-qrs-var spans present (markers 1–9, qualitative 1–4).
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Website spans and structural template text left unchanged.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No relevant ER section mapped to the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol/monitoring/benefit/risk labels derive from ER bold labels and table headers.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Labels faithful to ER (biomarker names and tier facts match source wording).
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji tier indicators in QRS body.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Content condensed to one-page card budget.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Metadata HTML comment is first element after doctype (lines 2–14).
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	YAML delimited by — opening and closing lines.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Inside HTML comment; not rendered.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Values trimmed; duration quoted (contains colon).
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: betaine_2026-0723-0012_Grok_ER.md
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02 matches QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0723-0043.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Grok.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word “Grok”.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Grok 4.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Grok 4” — nickname + version, no extra qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: betaine_2026-0723-0012_Grok_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Frontmatter values trimmed; quotes only where required.

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER `frontmatter` followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., `&` for `&`)	🟢	Title: “Betaine for Health & Longevity - Quick Reference Sheet” with &.
6.2	[header_topic] is set to the [canonical_topic] of the ER `frontmatter`, with HTML entities encoded as needed (e.g., `&` for `&`)	🟢	header_topic matches canonical_topic with entity encoding.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	header_subline_date 07/23/2026 from qrs_creation_date 2026-0723-0043.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	header_subline_model: Grok 4.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	No badge, AKA line, or extra header chrome.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER `Conclusion` section	🟢	Dense summary of ER Conclusion (homocysteine, strength, weak signals, GI/lipids, modest-dose tool).
7.2	[at_a_glance] is no longer than 60 words	🟢	57 words (≤60).
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each fact maps to Conclusion / Expected Benefits / Risks / Practical Considerations.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Plain language; “trimethylglycine” only as betaine synonym per ER; no specialist classification codes.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes, or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No effect sizes, RRs, or statistical results.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER `Key Interactions & Contraindications` section	🟢	Stop items from ER Key Interactions & Contraindications populations list (lines 295–300).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five ER contraindication populations represented.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Each stop item is an <li>.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Concise; trailing dash clause on renal item stripped; no citations/mechanisms.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Renal threshold parenthetical preserved (advanced CKD/dialysis), expanded for clarity.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER contraindications use no ranking (“>”) notation.
8.7	If no [stop_items] are present the section is left empty	N/A	Stop items are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER `Key Interactions & Contraindications` section	🟢	Caution items from ER Key Interactions & Contraindications (lines 289–294).
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Six interactions; none duplicated as contraindications.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Each caution item is an <li>.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Names only; severity/mitigation text stripped; no trailing dash clauses.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drugs/lists preserved in condensed parentheticals (methyl donors; lipid agents).
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER interactions use no ranking (“>”) notation.
9.7	If no [caution_items] are present the section is left empty	N/A	Caution items are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER `Protocol` section	🟢	Protocol cells derived from ER Therapeutic Protocol and Risk Mitigation (dose, form, splitting/food).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER `Protocol` section	🟢	Dose, Form, and Timing are the three core implementation aspects.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three actionable aspects present and used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER `Protocol` section.	🟢	All three action label/value/sub sets populated from ER.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Homocysteine, maximal strength, and lipid-change timelines from ER Practical Considerations (line 352).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered by related benefit magnitude: homocysteine (High) → strength (Medium) → lipids (remaining ER TTE).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three time-to-effect aspects present and used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All three time label/value/sub sets populated from ER.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the `Protocol Panel`	N/A	ER provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER `Expected Benefits` section	🟢	Benefits from ER Expected Benefits section.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four tier variables populated.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Tier lines are key facts only; magnitudes/study detail omitted.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical effect sizes or study notes in benefit lines.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers contain items from the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER `Potential Risks & Side Effects` section	🟢	Risks from ER Potential Risks & Side Effects section.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four tier variables populated.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Key facts only; frequencies and study detail omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	Parentheticals such as “(uncommon)” and “(TMAO)” stripped from risk lines.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers contain items from the ER.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER `Monitoring` section	🟢	Monitoring derived from ER Monitoring Protocol & Defining Success.
14.2	All measurable/quantifiable biomarkers from the `Monitoring` section are listed	🟢	All 9 table biomarkers listed (homocysteine through eGFR/creatinine).
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER `Monitoring` section. It is not left with placeholder text or empty.	🟢	Cadence covers baseline and 6–12 week / 6–12 month rechecks per ER.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER `Monitoring` section	🟢	Qualitative items from ER qualitative markers list.
15.2	All subjective/qualitative biomarkers from the `Monitoring` section are listed	🟢	All four ER qualitative markers present as qualitative_item_1–4.

Issues 23/07/2026 00:52

Pass rate 100.00%. No issues found.